Stockscreener 앱 받기
33.92
0.47%
0.16
전일 마감가:
$33.76
열려 있는:
$33.67
하루 거래량:
405.24K
Relative Volume:
0.43
시가총액:
$3.10B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-9.0938
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
+2.45%
1개월 성능:
+26.14%
6개월 성능:
-41.33%
1년 성능:
-28.14%
1일 변동 폭
$33.35
$34.10
1주일 범위
$32.20
$34.68
52주 변동 폭
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
CRNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
33.92 | 3.10B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.20 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.98 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.07 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
How To Trade (CRNX) - news.stocktradersdaily.com
Crinetics Pharmaceuticals Inc (CRNX) stock on the rise: An overview - uspostnews.com
Top investors say Crinetics Pharmaceuticals Inc (CRNX) ticks everything they need - Sete News
Recent Insider Activity Suggests Potential Gains for Crinetics Pharmaceuticals Inc (CRNX) - knoxdaily.com
LPL Financial LLC Acquires 1,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Market Watch Highlights: Crinetics Pharmaceuticals Inc (CRNX) Ends on an Upturn Note at 33.39 - DWinneX
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc. - Defense World
Are Crinetics Pharmaceuticals Inc (CRNX) shares a good deal now? - uspostnews.com
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
Crinetics Pharmaceuticals patents new SSTR3 agonists - BioWorld MedTech
Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World
JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
Key Investor Alert: Crinetics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stock Surge: Crinetics Pharmaceuticals Inc (CRNX) Closes at 26.89, Marking a -6.86 Increase/Decrease - DWinneX
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com
Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq
Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com
(CRNX) Trading Report - news.stocktradersdaily.com
Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia
Zurcher Kantonalbank Zurich Cantonalbank Purchases 2,970 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - The AM Reporter
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia
Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Mar 19 '25 |
Sale |
34.20 |
2,515 |
86,021 |
72,233 |
| Knight Jeff E. | Chief Operating Officer |
Mar 19 '25 |
Sale |
34.20 |
7,162 |
244,964 |
87,491 |
| Betz Stephen F. | Chief Scientific Officer |
Mar 19 '25 |
Sale |
34.20 |
5,770 |
197,353 |
108,588 |
| Struthers Richard Scott | President & CEO |
Mar 19 '25 |
Sale |
34.20 |
17,338 |
593,017 |
329,147 |
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Option Exercise |
16.89 |
5,000 |
84,450 |
36,748 |
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Sale |
39.07 |
5,000 |
195,350 |
31,748 |
0.52%
0.52%
자본화:
|
볼륨(24시간):